Skip to main content

Table 3 Total costs and QALYs gained

From: Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6

Alternative treatment

Genotype 1

Genotype 6

Total costs (Baht)

QALYs (Year)

ICER (compare to palliative care)

Total costs (Baht)

QALYs (Year)

ICER (compare to palliative care)

Palliative care

1,169,121

11.63

-

1,150,417

11.67

-

Peg 2a + RBV

747,718

13.44

Dominant

558,868

14.07

Dominant

Peg 2b + RBV

819,921

13.14

Dominant

655,697

13.69

Dominant